Medley began its work in the field of obesity around 1973. The anorexigen class of drugs was already presenting indications of growth beyond the Brazilian pharmaceutical market, mainly for the increasing awareness of the population about the risks related to obesity, but an effective and safe option didn’t exist.

And the step forward in this segment was taken in 1998 with the arrival of a new drug to the Brazilian market, as a result of the co-marketing partnership between Medley and Knoll (currently represented by Abbott).

The sibutramine cloridrate (PLENTY/REDUCTIL), revolutionized the concept of obesity treatment.

Its arrival onto the market gave specialists a long-term obesity treatment, enabling the cure to be based on diet reeducation, with sustainable weight loss instead of a sudden weight loss, with high chances for the accordion effect (weight loss – weight gain). Plenty (sibutramine cloridrate), conquered the leading position among the obesity treatment options and is currently one of the main drugs for weight loss and the improvement of other factors associated with the Metabolic Syndrome such as the HDL-cholesterol, triglycerides and glicemy levels.

Plenty (sibutramine cloridrate) is one of the main prescribed products from Medley and is among the 50 main products of the pharmaceutical industry in Brazil.